The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 31, 2019

Filed:

May. 04, 2016
Applicant:

Seoul National University R & Db Foundation, Seoul, KR;

Inventors:

Hyo-Soo Kim, Seoul, KR;

Jin Hur, Seoul, KR;

Jae Il Choi, Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 48/00 (2006.01); A61P 27/02 (2006.01); A61P 35/00 (2006.01); A61P 9/00 (2006.01); G01N 33/50 (2006.01); G01N 33/566 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61P 9/00 (2018.01); A61P 27/02 (2018.01); A61P 35/00 (2018.01); G01N 33/50 (2013.01); G01N 33/5023 (2013.01); G01N 33/566 (2013.01); G01N 33/574 (2013.01);
Abstract

Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.


Find Patent Forward Citations

Loading…